Chief Executive Officer
Over 20 years of experience as President and CEO of development stage biotechnology companies and manufacturers, both publicly and privately held, with technologies focused on inflammatory disease and cancer research. Negotiated licenses and sales agreements, has in-licensed technologies and has sponsored research projects with major universities across North America. A co-inventor on several biotechnology patents and applications.
Douglas K. Miller
Over 30 years of experience directing laboratories and projects for the identification and characterization of scientific targets and successful development of small molecule and biopharmaceutical therapeutics. Initiated and led teams within drug discovery, translational medicine, and early clinical development at Merck, Wyeth, Pfizer, Eisai, and Genesis Biotechnology focusing on inflammation and immunological and cardiovascular diseases. Established and directed multiple successful collaborations with diverse large pharma, biotech, academic, clinical, and government organizations to discover and validate biomarkers for disease incidence and progression and clinical patient selection. Author of over 85 publications and 7 patents and multiple abstracts and presentations.
Rolf Swenson, PhD
Dr. Swenson has over 20 years of experience in the pharmaceutical industry directing discovery research in different capacities. He contributed to programs in a large pharmaceutical company (Abbott Laboratories), a biotechnology company (Orchid Biosciences) from pre-IPO to post-IPO, and a private international imaging company (Bracco Diagnostics). He managed research groups focused on the discovery of new imaging and therapeutic agents, and on the development of novel devices that use microfluidic technology for genomic applications.
Dr. Swenson has over 46 publications in peer-reviewed journals and is an inventor on 65 US patents. His patented work includes a process to prepare the approved drug Zemplar (paricalcitol), and four therapeutic compounds and one diagnostic compound that have reached the clinic to treat or image cancer. He been in the drug discovery for 29 years.
Dr. Swenson’s BA is in Chemistry, with minors in mathematics and economics from University of California San Diego, and his PhD is in Organic Chemistry from Cornell University.